AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Xenon Pharmaceuticals Inc
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG002VBMLS5
35.34▼ 1.16 (-3.18%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
36.50
Day's Range
35.23 – 36.62
52-Week Range
33.38 – 72.66
Volume
619.5K
Avg Volume
2.3M
Share Statistics
Shares Outstanding
Employees
370
Exchange
XNAS
Listed
2014-11-05
Share count as of August 3, 2026

Xenon Pharmaceuticals Inc (XENE) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Xenon Pharmaceuticals Inc (XENE)
What is Xenon Pharmaceuticals Inc's Market Cap?
Xenon Pharmaceuticals Inc's Market Cap is $3.4B, based on as-reported figures from SEC (XBRL) filings.
What is Xenon Pharmaceuticals Inc's Enterprise Value?
Xenon Pharmaceuticals Inc's Enterprise Value is $2.5B, based on as-reported figures from SEC (XBRL) filings.
What is Xenon Pharmaceuticals Inc's EV / EBITDA?
Xenon Pharmaceuticals Inc's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Xenon Pharmaceuticals Inc's Revenue (TTM)?
Xenon Pharmaceuticals Inc's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Xenon Pharmaceuticals Inc's Net Income (TTM)?
Xenon Pharmaceuticals Inc's Net Income (TTM) is -$409.2M, based on as-reported figures from SEC (XBRL) filings.
What is Xenon Pharmaceuticals Inc's EBITDA?
Xenon Pharmaceuticals Inc's EBITDA is -$439.2M, based on as-reported figures from SEC (XBRL) filings.
What is Xenon Pharmaceuticals Inc's Diluted EPS (TTM)?
Xenon Pharmaceuticals Inc's Diluted EPS (TTM) is -4.23, based on as-reported figures from SEC (XBRL) filings.
What is Xenon Pharmaceuticals Inc's Net Debt?
Xenon Pharmaceuticals Inc's Net Debt is -$930.7M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · XENEAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Collaboration revenue (note 9)
YoY growth—-100.0%——
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue————
Loss from operations
% of revenue————
Other income:
Interest income
Unrealized fair value gain on trading securities————
Foreign exchange gain (loss)
Total other income
Loss before income taxes
Income tax recovery
Net loss
% of revenue————
Basic
Diluted